TachoSil® Versus Standard Haemostatic Treatment of Haemorrhage in Cardiovascular Surgery (TC-023-IM)

Phase 4

Completed

• Conditions: Haemorrhage; Haemostasis; Cardiovascular Surgery
• Interventions: Drug: fibrinogen (human) + thrombin (human); Drug: Standard haemostatic treatment in cardiovascular surgery

• Registration Number: NCT00440401
• Lead Sponsor: Nycomed

Brief Summary

To demonstrate efficacy and safety of TachoSil® in cardiovascular surgery

Detailed Description

Not available

Study Timeline

• Study Start: 2007-02
• Study First Submitted: 2007-02-26
• Study First Submitted QC: 2007-02-26
• Study First Posted: 2007-02-27
• Primary Completion: 2007-08
• Study Completion: 2007-11
• Results First Submitted: 2010-05-07
• Results First Submitted QC: 2010-05-07
• Results First Posted: 2010-06-04
• Status Verified: 2010-07
• Last Update Submitted: 2012-05-04
• Last Update Posted: 2012-05-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

All inclusion criteria must be answered "yes" for a subject to participate in the trial.

At Screening:

1. Has the subject given informed consent according to local requirements before any trial related activities? A trial related activity is any procedure that would not have been performed during the routine management of the subject. In this trial the screening is the first trial related activity.

2. For female subjects of childbearing potential: Is the pregnancy test at screening negative?

3. Does the female subject of childbearing potential use adequate contraception (contraceptive pill, contraceptive injection, contraceptive implant or intrauterine device)?

4. Is the subject ≥ 18 years of age?

5. Is the following planned: An elective surgery on the heart, the ascending aorta or arch, requiring cardiopulmonary bypass procedure?

   Intra operative (after primary haemostatic treatment):

6. Is bleeding from the heart muscle, the pericardium, a major vessel or a vascular bed that requires supportive haemostatic treatment present?

7. Has the area with the most problematic haemorrhage (target area) been identified? (please note that this must be done before randomisation).

8. Is it possible to compress the randomised treatment (TachoSil® or control fleece material) for 3 minutes?

Exclusion Criteria

All exclusion criteria must be answered "no" for a subject to participate in the trial.

At Screening:

1. Has the subject participated in any other trial with an investigational drug or device within 30 days before inclusion in this trial?

2. Does the subject participate in a clinical trial concomitantly with the present trial?

3. Is the subject undergoing an emergency operation?

4. Has the subject a history of allergic reactions after application of human fibrinogen, human thrombin and/or collagen of any origin?

5. Is the subject suffering from known coagulopathy?

6. Is the subject currently participating or has the subject previously participated in the TC-023-IM trial?

7. Is the female subject pregnant or breast feeding?

   Intra operative (after primary haemostatic treatment):

8. Has liquid fibrin sealant/glue or TachoSil® been applied?

9. Has the following occurred: Disseminated intravascular coagulation (DIC), i.e. micro vascular bleeding?

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
TachoSil®	fibrinogen (human) + thrombin (human)	-
Standard Treatment	Standard haemostatic treatment in cardiovascular surgery	Standard Treatment of haemorrhage in cardiovascular surgery

Primary Outcome Measures

Name	Time	Method
Proportion of Subjects Achieving Haemostasis at 3 Minutes	3 minutes	Three minutes after application of trial treatment (TachoSil® or standard fleece material) the investigator evaluated if haemostasis in the target area was achieved.

Secondary Outcome Measures

Name	Time	Method
Proportion of Subjects Achieving Haemostasis at 6 Minutes.	6 minutes	Six minutes after application of trial treatment (TachoSil® or standard fleece material) the investigator evaluated if haemostasis in the target area was achieved.

Trial Locations

Locations (1)

Nycomed; 🇩🇰 Roskilde, Denmark